Skip to main content
Premium Trial:

Request an Annual Quote

HTG Expands Collaboration With Merck KGaA

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said on Tuesday that it has signed a master new collaboration agreement with Merck KGaA, complementing an existing companion diagnostic agreement between the two companies.

The collaboration deal extends HTG's work with Merck beyond the two firms' initial CDx agreement, which was focused on the drugmaker's investigational Bruton's tyrosine kinase (BTK) inhibitor M7583, and into earlier research stages of Merck's drug programs. This will include a custom assay development program that HTG President and CEO T.J. Johnson said has already begun.

The custom profiling assay, designed for use on HTG EdgeSeq instruments, is intended to support biomarker research for six indications within Merck's drug development pipeline, HTG said.

The agreement also includes a statement of work specific to EMD Serono, Merck KGaA's biopharma business arm in the US and Canada.

In addition to the Merck agreements, HTG also announced a custom assay development deal with Daiichi Sankyo recently, and has been working under a master collaboration with Qiagen to combine the two firm's technologies and commercial strengths to attract new pharma customers.


The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.